Literature DB >> 20383518

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

O Fernández1, V Fernández, T Arbizu, G Izquierdo, I Bosca, R Arroyo, J A García Merino, E de Ramón.   

Abstract

Multiple sclerosis (MS) is a disease supposedly of autoimmune origin, with reactivity directed against myelin antigens. From the neuropathological point of view, MS produces inflammation, demyelination and axonal and neuronal degeneration. Inflammatory phenomena are predominant in the initial phase of the disease, followed later by neurodegenerative processes. Over the last decade, early treatment, during the most inflammatory phase of the disease, has been considered the best strategy to treat MS. Accordingly, we decided to determine the periods of delay between the first symptoms and the time to the first medical visit, the time to referral to a specialised MS unit, the delay in undertaking clinical and paraclinical tests, the diagnostic criteria used and the overall delay in diagnosis and treatment. The median time from onset of first symptoms to the first visit to a physician was 19.2 months, which represented the greatest delay. The median time between this initial medical consultation and the confirmation of the diagnosis by a specialised MS unit was 5.7 months, and the overall time from symptom onset to diagnosis was 24.9 months (2.08 years). The median time between onset of the first symptoms and the decision to give the first treatment was 2 years. The most important delay was that from symptom onset to the first medical visit, with the other delays being less. Thus, it is during this initial period that greater effort is required in order to reduce the time to diagnosis, by increasing awareness of the problem of MS among the general population and primary care physicians.

Entities:  

Mesh:

Year:  2010        PMID: 20383518     DOI: 10.1007/s00415-010-5560-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  56 in total

Review 1.  Neurophysiological investigations in multiple sclerosis.

Authors:  L Leocani; G Comi
Journal:  Curr Opin Neurol       Date:  2000-06       Impact factor: 5.710

2.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

3.  Longitudinal follow-up of "benign" multiple sclerosis at 20 years.

Authors:  Ana-Luiza Sayao; Virginia Devonshire; Helen Tremlett
Journal:  Neurology       Date:  2007-02-13       Impact factor: 9.910

4.  International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Authors:  M S Freedman; L D Blumhardt; B Brochet; G Comi; J H Noseworthy; M Sandberg-Wollheim; Sørensen P Soelberg
Journal:  Mult Scler       Date:  2002-02       Impact factor: 6.312

5.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

Review 6.  The natural history of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Neurol Clin       Date:  1995-02       Impact factor: 3.806

Review 7.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

8.  Clinical predictors of early second event in patients with clinically isolated syndrome.

Authors:  Ellen M Mowry; Mila Pesic; Barbara Grimes; Serina R Deen; Peter Bacchetti; Emmanuelle Waubant
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

9.  MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

Authors:  Jessica M Nielsen; Christoph Pohl; Chris H Polman; Frederik Barkhof; Mark S Freedman; Gilles Edan; David H Miller; Lars Bauer; Rupert Sandbrink; Ludwig Kappos; Bernard M J Uitdehaag
Journal:  BMC Neurol       Date:  2009-05-20       Impact factor: 2.474

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  11 in total

Review 1.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

2.  Hindsight is 20/20.

Authors:  Alexander T Moffett; Harry Hollander; Gail Berkenblit; Justin C McArthur; Reza Manesh
Journal:  J Hosp Med       Date:  2020-02-11       Impact factor: 2.960

3.  The Prevalence of Bipolar Disorders and Association With Quality of Life in a Cohort of Patients With Multiple Sclerosis.

Authors:  Adalia H Jun-O'Connell; Ankur Butala; Idanis Berrios Morales; Nils Henninger; Kristina M Deligiannidis; Nancy Byatt; Carolina Ionete
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2016-08-19       Impact factor: 2.198

4.  Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring.

Authors:  Enrique Alcalde-Cabero; Javier Almazán-Isla; Antonio García-Merino; Joao de Sá; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2013-06-12       Impact factor: 2.474

5.  Early recognition of multiple sclerosis using natural language processing of the electronic health record.

Authors:  Herbert S Chase; Lindsey R Mitrani; Gabriel G Lu; Dominick J Fulgieri
Journal:  BMC Med Inform Decis Mak       Date:  2017-02-28       Impact factor: 2.796

6.  Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.

Authors:  Marco Kaufmann; Jens Kuhle; Milo A Puhan; Christian P Kamm; Andrew Chan; Anke Salmen; Jürg Kesselring; Pasquale Calabrese; Claudio Gobbi; Caroline Pot; Nina Steinemann; Stephanie Rodgers; Viktor von Wyl
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-12-06

7.  A computer-aided diagnosis of multiple sclerosis based on mfVEP recordings.

Authors:  Luis de Santiago; E M Sánchez Morla; Miguel Ortiz; Elena López; Carlos Amo Usanos; M C Alonso-Rodríguez; R Barea; Carlo Cavaliere-Ballesta; Alfredo Fernández; Luciano Boquete
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

8.  How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.

Authors:  Laura Barin; Christian P Kamm; Anke Salmen; Holger Dressel; Pasquale Calabrese; Caroline Pot; Sven Schippling; Claudio Gobbi; Stefanie Müller; Andrew Chan; Stephanie Rodgers; Marco Kaufmann; Vladeta Ajdacic-Gross; Nina Steinemann; Jürg Kesselring; Milo A Puhan; Viktor von Wyl
Journal:  Mult Scler       Date:  2019-01-18       Impact factor: 6.312

9.  Social value of a set of proposals for the ideal approach of multiple sclerosis within the Spanish National Health System: a social return on investment study.

Authors:  Ester Moral Torres; Óscar Fernández Fernández; Pedro Carrascal Rueda; Elena Ruiz-Beato; Elvira Estella Pérez; Rita Manzanares Estrada; Teresa Gómez-García; Margarita Jiménez; Álvaro Hidalgo-Vega; María Merino
Journal:  BMC Health Serv Res       Date:  2020-02-04       Impact factor: 2.655

10.  Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study.

Authors:  Sherif M Hamdy; Maged Abdel-Naseer; Nevin M Shalaby; Alaa N Elmazny; Ahmed A Nemr; Amr Hassan; Mohamed I Hegazy; Husam S Mourad; Nirmeen A Kishk; Mona A Nada; Ahmed Abdelalim; Amr M Fouad; Hatem S Shehata
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-18       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.